Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.

Shukui QinJin LiHaijun ZhongChuan JinLili ChenXianglin YuanQingxia FanKehe ChenPeiguo CaoJianjun XiaoDa JiangTao ZhangHongyu ZhangXicheng WangWei WangLin HanQingyu WangJun Zhunull null

Published in: British journal of cancer (2022)

NCT03941574.

Keyphrases

clinical trial
study protocol
open label
cross sectional
double blind
genetic diversity